Dr. Kelvin Teo

Adjunct A/Prof. Teo is senior consultant ophthalmologist at Advanced Eye Clinic and Surgery with specific interests in retina diseases in the eye. He is an accomplished cataract surgeon and retinal specialist, with interest in age related macular degeneration, diabetic eye disease and retinal vascular disorders.

He graduated from the Barts and the London School of Medicine and Dentistry and obtained his PhD in Medical Research from the University of Sydney. Dr Teo completed his ophthalmology specialist training in the Singapore National Eye Centre (SNEC). He practised in SNEC for over 10 years with 2 fellowships in Medical Retina, one from SNEC and the other from Sydney Eye Hospital, University of Sydney where he also obtained his PhD in Medical Research.

A/Prof Teo continues his academic pursuits as an adjunct Associate Professor at the Ophthalmology & Visual Sciences Academic Clinical Programme (EYE ACP) Duke NUS Medical School and a lead researcher at the Singapore Eye Research Institute (SERI) with a focus on the aging eye and age related macular degeneration. He has published more than 100 peer review papers and was awarded numerous grants including the prestigious National Medical Research Council, (NMRC) Transition Award.

This unique blend of clinical experience and strong research expertise makes him a key opinion leader in advancing the field of medical retina and allows him to provide the latest and most novel and effective management for conditions affecting the eye and retina.

Cataract Surgery, low vision enhancement surgery, Intra vitreal Injections, Laser treatments for the retina, treatments for other general eye conditions

Low vision enhancement surgery, Intra vitreal Injections, Laser treatments for the retina

1. Khor W-B, Teo KY, Mehta JS, Tan DT. Descemet stripping automated endothelial keratoplasty in complex eyes: results with a donor insertion device. Cornea 2013;32(8):1063-8.
2. Teo K, Cheung CMG. Choroidal neovascularization secondary to pathological myopia. World 2014;3.
3. Teo KY, Cheung GC, Lee SY, et al. Evolving practice patterns in treatment of major retinal diseases in Singapore. Annals of the Academy of Medicine, Singapore 2014;43(3):192-4.
4. Chan NS-W, Teo K, Cheung CMG. Epidemiology and diagnosis of myopic choroidal neovascularization in Asia. Eye & Contact Lens 2016;42(1):48-55.
5. Cheng C, Teo K, Tan CS, et al. Myopic retinoschisis in Asians: structural features and determinants of visual acuity and prognostic factors for progression. Retina 2016;36(4):717-26.
6. Tan AC, Teo K, Guan OS, Koh A. Long-term outcomes of myopic choroidal neovascularisation treated with combined ranibizumab and dexamethasone characterised by multi-modal imaging. Graefe’s Archive for Clinical and Experimental Ophthalmology 2016;254:1881-8.
7. Teo KYC, Ng WY, Lee SY, Cheung CMG. Management of Myopic Choroidal Neovascularization: focus on anti-VEGF therapy. Drugs 2016;76:1119-33.
8. Cheung N, Teo K, Zhao W, et al. Prevalence and associations of retinal emboli with ethnicity, stroke, and renal disease in a multiethnic Asian population: The Singapore Epidemiology of Eye Disease Study. JAMA ophthalmology 2017;135(10):1023-8.
9. Lo YL, Najjar RP, Teo KY, et al. A reappraisal of diagnostic tests for myasthenia gravis in a large Asian cohort. Journal of the Neurological Sciences 2017;376:153-8.
10. Mitchell P, Cheng C-Y, Cheung N, et al. Prevalence and associations of retinal emboli with ethnicity, stroke, and renal disease in a multiethnic Asian population: The Singapore epidemiology of eye disease study. 2017.
11. Patil R, Wong CW, Michelet F, et al. Angiogenesis-based therapies for eye diseases. Biochemical Basis and Therapeutic Implications of Angiogenesis 2017:259-97.
12. Tan CSA, Teo K, Devarajan K, et al. A NOVEL PARAMETER TO ASSESS CHOROIDAL VASCULATURE FOR THE DETECTION PACHYCHOROID DISEASE. CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY: WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, 2017; v. 45.
13. Cornish EE, Teo KY, Gillies MC, et al. 5 YEAR OUTCOMES FROM THE BEVORDEX TRIAL (BEVACIZUMAB OR DEXAMETHASONE IMPLANT FOR DMO). Clinical and Experimental Ophthalmology 2018;46:44-5.
14. Cornish EE, Teo KYC, Gillies MC, et al. Five year outcomes of the Bevordex Study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative ophthalmology & visual science 2018;59(9):4847-.
15. Nguyen V, Teo K, Simpson J, et al. A Probabilistic Forecast of 12 Month Visual Outcomes of nAMD. Investigative Ophthalmology & Visual Science 2018;59(9):829-.
16. Teo K, Lee SY, Constable I. The effect of Surgical removal of the Internal Limiting Membrane on AAV vector delivery to the Retina in a Non-Human Primate model. Investigative Ophthalmology & Visual Science 2018;59(9):5660-.
17. Teo KY, Tow SL, Haaland B, et al. Low conversion rate of ocular to generalized myasthenia gravis in Singapore. Muscle & Nerve 2018;57(5):756-60.
18. Teo KYC, Gillies M, Fraser-Bell S. The use of vascular endothelial growth factor inhibitors and complementary treatment options in polypoidal choroidal vasculopathy: a subtype of neovascular age-related macular degeneration. International journal of molecular sciences 2018;19(9):2611.
19. Teo KYC, Lee SY, Barathi AV, et al. Surgical removal of internal limiting membrane and layering of AAV vector on the retina under air enhances gene transfection in a nonhuman primate. Investigative Ophthalmology & Visual Science 2018;59(8):3574-83.
20. Teo KYC, Wong CW, Tsai ASH, et al. Swept-Source Optical Coherence Tomography: A Color Atlas. World Scientific, 2018.
21. Teo KYC, Yanagi Y, Lee SY, et al. Comparison of optical coherence tomography angiographic changes after anti–vascular endothelial growth factor therapy alone or in combination with photodynamic therapy in polypoidal choroidal vasculopathy. Retina 2018;38(9):1675-87.
22. Zumbansen M, Ong S-P, Teo KYC, et al. Validation of a Novel Cytokine Multiplex Assay for Vitreous Analysis in Diabetic Retinopathy. Investigative Ophthalmology & Visual Science 2018;59(9):5362-.
23. Ang MHN, Teo KYC, Tan ACS. An injection and extraction ophthalmic device. US Patent App. 16/091,177, 2019.
24. Cheung CMG, Grewal DS, Teo KYC, et al. The evolution of fibrosis and atrophy and their relationship with visual outcomes in Asian persons with neovascular age-related macular degeneration. Ophthalmology Retina 2019;3(12):1045-55.
25. Cornish E, Teo K, Nguyen V, et al. 5-year visual acuity outcomes for intravitreal therapy in bilateral neovascular age-related macular degeneration-fight retinal blindness (FRB!) project. CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY: WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, 2019; v. 47.
26. Gandhi M, Ang M, Teo K, et al. EQ-5D-5L is more responsive than EQ-5D-3L to treatment benefit of cataract surgery. The Patient-Patient-Centered Outcomes Research 2019;12:383-92.
27. Gandhi M, Janssen M, Ang M, et al. A vision’bolt-on’to EQ-5D is more responsive than EQ-5D in patients undergoing cataract surgery. QUALITY OF LIFE RESEARCH: SPRINGER VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS, 2019; v. 28.
28. Invernizzi A, Nguyen V, Teo K, et al. Five-year real-world outcomes of occult and classic choroidal neovascularization: data from the Fight Retinal Blindness! Project. American journal of ophthalmology 2019;204:105-12.
29. Invernizzi A, Teo K, Nguyen V, et al. Type 3 neovascularisation (retinal angiomatous proliferation) treated with antivascular endothelial growth factor: real-world outcomes at 24 months. British Journal of Ophthalmology 2019;103(9):1337-41.
30. Teo KY, Cheung GC. New concepts in polypoidal choroidal vasculopathy imaging: a focus on optical coherence tomography and optical coherence tomography angiography. The Asia-Pacific Journal of Ophthalmology 2019;8(2):165-71.
31. Teo KYC, Squirrell DM, Nguyen V, et al. A multicountry comparison of real-world management and outcomes of polypoidal choroidal vasculopathy: Fight retinal blindness! Cohort. Ophthalmology Retina 2019;3(3):220-9.
32. Tey KY, Teo K, Tan A, et al. Optical coherence tomography angiography in diabetic retinopathy: a review of current applications. Eye and Vision 2019;6(1):1-10.
33. Cheong KX, Grewal DS, Teo KYC, et al. The relationship between pigment epithelial detachment and visual outcome in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Eye 2020;34(12):2257-63.
34. Cheong KX, Lee SY, Ang M, Teo KYC. Vessel density changes on optical coherence tomography angiography after vascular endothelial growth factor inhibitor treatment for diabetic macular edema. Turkish Journal of Ophthalmology 2020;50(6):343.
35. CHEONG KX, LEE SY, ANG M, TEO KYC. Diyabetik Maküla Ödeminin Vasküler Endotelyal Büyüme Faktörü İnhibitörü ile Tedavisi Sonrası Optik Koherens Tomografi Anjiyografide Damar Yoğunluğu Değişimleri. Türk Oftalmoloji Dergisi 2020;50(6):343-50.
36. Cheung CMG, Teo KYC, Tun SBB, et al. Differential reperfusion patterns in retinal vascular plexuses following increase in intraocular pressure an OCT angiography study. Scientific Reports 2020;10(1):16505.
37. Fenner BJ, Ting DS, Tan AC, et al. Real-world treatment outcomes of age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Ophthalmology Retina 2020;4(4):403-14.
38. Gandhi M, Ang M, Teo K, et al. A vision ‘bolt-on’increases the responsiveness of EQ-5D: preliminary evidence from a study of cataract surgery. The European Journal of Health Economics 2020;21:501-11.
39. Invernizzi A, Pellegrini M, Cornish E, et al. Imaging the choroid: from indocyanine green angiography to optical coherence tomography angiography. The Asia-Pacific Journal of Ophthalmology 2020;9(4):335-48.
40. Perez JM, Teo K, Ong R, et al. Optical coherence tomography characteristics of taxane-induced macular edema and other multimodal imaging findings. Graefe’s Archive for Clinical and Experimental Ophthalmology 2020;258:1607-15.
41. Shen W, Teo KYC, Wood JP, et al. Preclinical and clinical studies of photobiomodulation therapy for macular oedema. Diabetologia 2020;63:1900-15.
42. Teo KYC, Chan RP, Cheung CMG. Keeping our eyecare providers and patients safe during the COVID-19 pandemic. Eye 2020;34(7):1161-2.
43. Teo KYC, Joe AW, Nguyen V, et al. Prevalence and risk factors for the development of physician-graded subretinal fibrosis in eyes treated for neovascular age-related macular degeneration. Retina 2020;40(12):2285-95.
44. Teo KYC, Mohla A, Cheung CMG. Comparison of vascular endothelial growth factor inhibitors on macular oedema secondary central retinal vein occlusion. Eye 2020;34(2):221-2.
45. Teo KYC, Saxena N, Gan A, et al. Detrimental effect of delayed re-treatment of active disease on outcomes in neovascular age-related macular degeneration: the RAMPS study. Ophthalmology Retina 2020;4(9):871-80.
46. Tsai AS, Gan AT, Ting DS, et al. Diabetic macular ischemia: correlation of retinal vasculature changes by optical coherence tomography angiography and functional deficit. Retina 2020;40(11):2184-90.
47. Cheong KX, Barathi VA, Teo KYC, et al. Choroidal and retinal changes after systemic adrenaline and photodynamic therapy in non-human primates. Investigative Ophthalmology & Visual Science 2021;62(3):25-.
48. Cheong KX, Teo AWJ, Cheung CMG, et al. Association between retinal thickness variation and visual acuity change in neovascular age‐related macular degeneration. Clinical & Experimental Ophthalmology 2021;49(5):430-8.
49. Cheong KX, Teo KYC, Cheung CMG. Influence of pigment epithelial detachment on visual acuity in neovascular age-related macular degeneration. Survey of Ophthalmology 2021;66(1):68-97.
50. Cheung CMG, Lai TY, Teo K, et al. Polypoidal choroidal vasculopathy: consensus nomenclature and non–indocyanine green angiograph diagnostic criteria from the Asia-pacific ocular imaging society PCV workgroup. Ophthalmology 2021;128(3):443-52.
51. Cheung CMG, Teo KYC, Spaide RF. Pulsatile filling of dilated choroidal vessels in macular watershed zones. Retina 2021;41(11):2370-7.
52. Cheung CMG, Teo KYC, Tun SBB, et al. Correlation of choriocapillaris hemodynamic data from dynamic indocyanine green and optical coherence tomography angiography. Scientific Reports 2021;11(1):1-10.
53. Cornish EE, Teo KY, Nguyen V, et al. Five-year incidence and visual acuity outcomes for intravitreal therapy in bilateral neovascular age-related macular degeneration: Fight Retinal Blindness! Project. Retina 2021;41(1):118-24.
54. Invernizzi A, Parrulli S, Monteduro D, et al. Outer retinal layer thickening predicts the onset of exudative neovascular age-related macular degeneration. American Journal of Ophthalmology 2021;231:19-27.
55. Islam M, Sansome S, Das R, et al. Smartphone-based remote monitoring of vision in macular disease enables early detection of worsening pathology and need for intravitreal therapy. BMJ Health & Care Informatics 2021;28(1).
56. Jordan-Yu JM, Teo K, Fan Q, et al. T and genetic variations between Asian and Caucasian polypoidal choroidal vasculopathy. British Journal of Ophthalmology 2021;105(12):1716-23.
57. Jordan-Yu JM, Teo KYC, Chakravarthy U, et al. Polypoidal choroidal vasculopathy features vary according to subfoveal choroidal thickness. Retina 2021;41(5):1084-93.
58. Kahn SA, Bousvaros A, Vernon-Roberts A, et al. Secondary Logo Journal Logo. Blood Pressure Monitoring 2021;26(5):348-56.
59. Kandel H, Nguyen V, Gillies MC, Watson SL. Quality of life impact of eye diseases: a save sight registries study. Investigative Ophthalmology & Visual Science 2021;62(8):3495-.
60. Rim TH, Lee AY, Ting DS, et al. Detection of features associated with neovascular age-related macular degeneration in ethnically distinct data sets by an optical coherence tomography: trained deep learning algorithm. British Journal of Ophthalmology 2021;105(8):1133-9.
61. Sim SS, Yip MY, Wang Z, et al. Digital technology for AMD management in the post-COVID-19 new normal. The Asia-Pacific Journal of Ophthalmology 2021;10(1):39-48.
62. Song Y, Tham Y-C, Chong C, et al. Patterns and determinants of choroidal thickness in a multiethnic Asian population: the Singapore Epidemiology of Eye Diseases Study. Ophthalmology Retina 2021;5(5):458-67.
63. Tan G, Teo KYC, Tsai A, et al. Evaluation of an ophthalmic grader led virtual imaging clinic pathway in the management of patients with retina diseases. Investigative Ophthalmology & Visual Science 2021;62(8):1934-.
64. Tan T-E, Fenner BJ, Barathi VA, et al. Gene-based therapeutics for acquired retinal disease: opportunities and progress. Frontiers in Genetics 2021;12:795010.
65. Teo KYC, Bachmann LM, Sim D, et al. Patterns and characteristics of a clinical implementation of a self-monitoring program for retina diseases during the COVID-19 pandemic. Ophthalmology Retina 2021;5(12):1245-53.
66. Teo KYC, Cheong KX, Ong R, et al. Macular neovascularization in eyes with pachydrusen. Scientific reports 2021;11(1):7495.
67. Teo KYC, Nguyen V, Barthelmes D, et al. Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence. Eye 2021;35(10):2793-801.
68. Teo KYC, Sadda SR, Cheung CMG, et al. Non-ICGA treatment criteria for suboptimal anti-VEGF response for polypoidal choroidal vasculopathy: APOIS PCV Workgroup report 2. Ophthalmology Retina 2021;5(10):945-53.
69. Teo KYC, Yanagi Y, Wong TY, et al. Morphologic predictors and temporal characteristics of conversion from nonexudative to exudative age-related macular degeneration in the fellow eye. Ophthalmology Retina 2021;5(2):126-40.
70. Tsai AS, Jordan-Yu JM, Gan AT, et al. Diabetic macular ischemia: influence of optical coherence tomography angiography parameters on changes in functional outcomes over one year. Investigative Ophthalmology & Visual Science 2021;62(1):9-.
71. Vyas CH, Cheung CMG, Tan C, et al. Multicentre, randomised clinical trial comparing intravitreal aflibercept monotherapy versus aflibercept combined with reduced-fluence photodynamic therapy (RF-PDT) for the treatment of polypoidal choroidal vasculopathy. BMJ open 2021;11(7):e050252.
72. Yanagi Y, Chuan RYM, Shihabuddeen WA, et al. Causal Association of Serum Cholesterol Efflux Capacity and Polypoidal Choroidal Vasculopathy of Singapore Chinese Population. Investigative Ophthalmology & Visual Science 2021;62(8):2732-.
73. Chay J, Fenner BJ, Finkelstein EA, et al. Real-world cost-effectiveness of anti-VEGF monotherapy and combination therapy for the treatment of polypoidal choroidal vasculopathy. Eye 2022;36(12):2265-70.
74. Cheong KX, Cheung CMG, Teo KYC. Review of fibrosis in neovascular age-related macular degeneration. American journal of ophthalmology 2022.
75. Cheong KX, Teo KYC, Tham YC, et al. Three-dimensional modelling of the choroidal angioarchitecture in a multi-ethnic Asian population. Scientific Reports 2022;12(1):3831.
76. Cheung CMG, Fawzi A, Teo KY, et al. Diabetic macular ischaemia-a new therapeutic target? Progress in Retinal and Eye Research 2022;89:101033.
77. Cheung CMG, Wong MYZ, Teo KYC. Choroidal vascular alterations in age-related macular degeneration and polypoidal choroidal vasculopathy. Retina 2022:10.1097.
78. Chong Teo KY, Nguyen V, Gemmy Cheung CM, et al. The impact of disease activity on 5-year outcomes in patients undergoing treatment for neovascular age-related macular degeneration. Retina 2022;42(1):95-106.
79. Corvi F, Chandra S, Invernizzi A, et al. Multimodal imaging comparison of Polypoidal choroidal vasculopathy between Asian and Caucasian populations. American journal of ophthalmology 2022;234:108-16.
80. Fenner BJ, Cheung CMG, Sim SS, et al. Evolving treatment paradigms for PCV. Eye 2022;36(2):257-65.
81. Fenner BJ, Tan T-E, Barathi AV, et al. Gene-based therapeutics for inherited retinal diseases. Frontiers in genetics 2022;12:794805.
82. Fenner BJ, Teo KY, Tham YC, et al. Prevalence of Polypoidal Choroidal Vasculopathy Using Non-indocyanine green angiography–based Criteria. Ophthalmology Retina 2022;6(2):179-81.
83. Invernizzi A, Staurenghi G, Cheung CMG, Teo KYC. Reply to Comment on:” Outer Retinal Layer Thickening Predicts the Onset of Exudative Neovascular Age-Related Macular Degeneration”. American journal of ophthalmology 2022;235:330-1.
84. Kandel H, Nguyen V, Piermarocchi S, et al. Quality of life impact of eye diseases: a Save Sight Registries study. Clinical & Experimental Ophthalmology 2022;50(4):386-97.
85. Man REK, Gan ATL, Fenwick EK, et al. Impact of incident age-related macular degeneration and associated vision loss on vision-related quality of life. British Journal of Ophthalmology 2022;106(8):1063-8.
86. Ozdemir S, Finkelstein E, Lee JJ, et al. Understanding patient preferences in anti-VEGF treatment options for age-related macular degeneration. Plos one 2022;17(8):e0272301.
87. Rim TH, Lee AY, Ting DS, et al. Computer-aided detection and abnormality score for the outer retinal layer in optical coherence tomography. British Journal of Ophthalmology 2022;106(9):1301-7.
88. Sim SS, Vyas CH, Gunatheesan R, et al. Infographic:” Planet Trial: Intravitreal aflibercept monotherapy for polypoidal choroidal vasculopathy (PCV)”. Eye (London, England) 2022;36(6):1142.
89. Sun CZ, Sim SSKP, Vyas CH, et al. Infographic: non-ICGA imaging for polypoidal choroidal vasculopathy (PCV)-Asia-Pacific Ocular Imaging Society PCV workgroup report 1 & 2. Eye (London, England) 2022;36(6):1143.
90. Takahashi K, Song Y, Cheong KX, et al. Pattern and characteristics of drusen subtypes in Chinese and Indian populations in Singapore. RETINA 2022:10.1097.
91. Tan A, Jordan-Yu JM, Vyas CH, et al. Optical coherence tomography features of polypoidal lesion closure in polypoidal choroidal vasculopathy treated with aflibercept. Retina 2022;42(1):114-22.
92. Teo KY, Fujimoto S, Sadda SR, et al. Geographic atrophy phenotypes in subjects of different ethnicity: Asia-Pacific Ocular Imaging Society Workgroup Report 3. Ophthalmology Retina 2022.
93. Teo KY, Invernizzi A, Staurenghi G, Cheung CMG. COVID-19-related retinal micro-vasculopathy–A review of current evidence. American Journal of Ophthalmology 2022;235:98-110.
94. Teo KY, Nguyen V, O’Toole L, et al. Longer treatment intervals are associated with reduced treatment persistence in neovascular age related macular degeneration. Eye 2022:1-7.
95. Teo KY, Vyas C, Sun C, et al. Five-year incidence of fellow eye neovascular involvement in age-related macular degeneration and polypoidal choroidal vasculopathy in an Asian population. RETINA 2022:10.1097.
96. Teo KYC, Jordan-Yu JM, Tan AC, et al. Efficacy of a novel personalised aflibercept monotherapy regimen based on polypoidal lesion closure in participants with polypoidal choroidal vasculopathy. British Journal of Ophthalmology 2022;106(7):987-93.
97. Tey KY, Hoang QV, Loh IQ, et al. Multimodal Imaging-Based Phenotyping of a Singaporean Hospital-Based Cohort of High Myopia Patients. Frontiers in Medicine 2022;8:670229.
98. Tham Y-C, Husain R, Teo KYC, et al. New digital models of care in ophthalmology, during and beyond the COVID-19 pandemic. British Journal of Ophthalmology 2022;106(4):452-7.
99. Vyas CH, Cheung CMG, Jordan-Yu JMN, et al. Novel volumetric imaging biomarkers for assessing disease activity in eyes with PCV. Scientific Reports 2022;12(1):2993.
100. Vyas CH, Lott PW, Gunatheesan R, et al. Infographic: Everest II study” Which is superior? Combination therapy or monotherapy for polypoidal choroidal vasculopathy (PCV) treatment”. Eye (London, England) 2022;36(6):1140-1.
101. Yanagi Y, Richard M, Ahamed W, et al. Serum Cholesterol Efflux Capacity in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. Ophthalmology Science 2022;2(2):100142.
102. Cheung G, Al-Shaaibi M, Teo K. Diabetic Macular Ischemia and Anti-VEGF Therapy. Diabetic Macular Edema: Springer Nature Singapore Singapore, 2023.
103. Cornish EE, Teo KY, Gillies MC, et al. Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema. British Journal of Ophthalmology 2023;107(1):79-83.
104. Fenner BJ, Li H, Gan AT, et al. Genetic Variability of Complement Factor H Has Ethnicity-Specific Associations With Choroidal Thickness. Investigative Ophthalmology & Visual Science 2023;64(2):10-.
105. Khachigian LM, Liew G, Teo KY, et al. Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. Journal of Translational Medicine 2023;21(1):133.
106. Loo J, Teo KY, Vyas CH, et al. Joint multimodal deep learning-based automatic segmentation of ICGA and OCT images for assessment of PCV biomarkers. Ophthalmology Science 2023:100292.
107. Tan AC, Chee ML, Fenner BJ, et al. Six-year incidence of age-related macular degeneration and correlation to OCT-derived drusen volume measurements in a Chinese population. British Journal of Ophthalmology 2023;107(3):392-8.
108. Teo KYC. Real-world evidence for neovascular age-related macular degeneration: a practical approach. Eye 2023;37(1):1-3.
109. Wong WM, Sun W, Vyas C, et al. Analysis of the pachychoroid phenotype in an Asian population: methodology and baseline study population characteristics. British Journal of Ophthalmology 2023.

Adjunct Associate Professor, Duke NUS, Eye ACP

Associate Lecturer, University of Sydney, Save Sight Institute

Theme Principle Investigator, Translational Asian Age-related macular degeneration Programme (TAAP)

Macular Society, Member

International Steering Committee, Fight Retinal Blindness Registry, Member

International Retina Imaging Society, Member